40 research outputs found

    Androgen-Regulated Transcriptional Control of Sialyltransferases in Prostate Cancer Cells

    Get PDF
    The expression of gangliosides is often associated with cancer progression. Sialyltransferases have received much attention in terms of their relationship with cancer because they modulate the expression of gangliosides. We previously demonstrated that GD1a production was high in castration-resistant prostate cancer cell lines, PC3 and DU145, mainly due to their high expression of β-galactoside α2,3-sialyltransferase (ST3Gal) II (not ST3Gal I), and the expression of both ST3Gals was regulated by NF-κB, mainly by RelB. We herein demonstrate that GD1a was produced in abundance in cancerous tissue samples from human patients with hormone-sensitive prostate cancers as well as castration-resistant prostate cancers. The expression of ST3Gal II was constitutively activated in castration-resistant prostate cancer cell lines, PC3 and DU145, because of the hypomethylation of CpG island in its promoter. However, in androgen-depleted LNCap cells, a hormone-sensitive prostate cancer cell line, the expression of ST3Gal II was silenced because of the hypermethylation of the promoter region. The expression of ST3Gal II in LNCap cells increased with testosterone treatment because of the demethylation of the CpG sites. This testosterone-dependent ST3Gal II expression was suppressed by RelB siRNA, indicating that RelB activated ST3Gal II transcription in the testosterone-induced demethylated promoter. Therefore, in hormone-sensitive prostate cancers, the production of GD1a may be regulated by androgen. This is the first report indicating that the expression of a sialyltransferase is transcriptionally regulated by androgen-dependent demethylation of the CpG sites in its gene promoter

    DECIGO and DECIGO pathfinder

    Full text link

    SYMPATHETIC BLOCKADE AFTER STELLATE GANGLION BLOCK : A CONTINUOUS RECORDING USING SKIN POTENTIAL ACTIVITY

    No full text
    Skin potential activities (SPA) were used to assess the degree of sympathetic blockade after stellate ganglion block (SGB). The SPA were recorded bilaterally from the palmar thenar eminences in four outpatients before and after SGB. Before the SGB, the skin potential responses (SPR) on both sides were synchronous and their amplitudes were almost the same. After SGB, the SPR amplitude on the blocked side gradually fell from 1-2 minutes. Before SGB, the skin potential levels (SPL) on both sides were parallel and the lateral difference was constant. About 1-2 minutes after SGB, the SPL on the blocked side began to fall and then reached a stationary level 5 minutes after SGB. SPA variations due to factors other than peripheral blockade can be cancelled by bilateral recording. Thus, the net SPL decrease on the blocked side compared with that on the non-blocked side was proved to be a useful index for continuous, quantitative monitoring of the sympathetic blockade by the SGB

    In vivo imaging of transplanted islets labeled with a novel cationic nanoparticle.

    Get PDF
    To monitor pancreatic islet transplantation efficiency, reliable noninvasive imaging methods, such as magnetic resonance imaging (MRI) are needed. Although an efficient uptake of MRI contrast agent is required for islet cell labeling, commercially-available magnetic nanoparticles are not efficiently transduced into cells. We herein report the in vivo detection of transplanted islets labeled with a novel cationic nanoparticle that allowed for noninvasive monitoring of islet grafts in diabetic mice in real time. The positively-charged nanoparticles were transduced into a β-cell line, MIN6 cells, and into isolated islets for 1 hr. MRI showed a marked decrease in the signal intensity on T1- and T2-weighted images at the implantation site of the labeled MIN 6 cells or islets in the left kidneys of mice. These data suggest that the novel positively-charged nanoparticle could be useful to detect and monitor islet engraftment, which would greatly aid in the clinical management of islet transplant patients
    corecore